Loading
Instead of opening a trial at fifty hospitals and waiting for patients, keep a network of pre-vetted clinics ready and switch a trial on where a matching patient is found.
A network of community and academic sites holds master agreements, a central IRB, standing budgets and trained staff; when a matched patient is identified (via matching tools or referral), the site is activated for that protocol within 10-14 days. TAPUR and some rare-tumour and biomarker-defined trials have used this model; the idea is to make it the default for biomarker-selected phase 2 and rare-cancer trials and to fund the network as infrastructure.
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.
Shares Basket, umbrella, and platform trials, Trials enrol too few, too slowly, Rare and paediatric cancers without markets.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.
Shares American Society of Clinical Oncology (ASCO), Basket, umbrella, and platform trials, Rare and paediatric cancers without markets.
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly.